Phathom Pharmaceuticals, Inc.

Clinical trials sponsored by Phathom Pharmaceuticals, Inc., explained in plain language.

Phathom Pharmaceuticals, Inc. PHAT NASDAQ

A biopharmaceutical company developing gastrointestinal treatments.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New pill could ease swallowing for EoE patients Results expected Oct 2026 (estimated) May already have reported ↗

Browse trials soon ready across all sponsors →

Trials to join now! 1 Not yet recruiting 1 Not yet finished but already full! 1 Completed 1

Heartburn drug under the microscope: registry tracks thousands of pregnancies

Knowledge-focused Recruiting now

Researchers are running an observational registry to study whether vonoprazan, an oral drug for heartburn and acid reflux, is safe to take during pregnancy. The study follows women aged 15 to 50 who took vonoprazan while pregnant and compares their outcomes with women who did not…

Sponsor: Phathom Pharmaceuticals, Inc. • Aim: Knowledge-focused

Last updated Sep 20, 2026 00:00 UTC

Phathom Pharmaceuticals, Inc.

Upcoming readouts

Heartburn drug under the microscope: registry tracks thousands of pregnancies